Plain-English translation of NCT06959550 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can help people with metastatic colorectal cancer (cancer that has spread beyond the colon or rectum) whose disease has continued to grow despite previous treatments. is a new type of antibody that works by boosting your immune system in two different ways simultaneously. The study is divided into three groups based on specific characteristics of each person's cancer to see if the treatment works differently depending on those features.
Colorectal cancer that has spread and stopped responding to standard chemotherapy and immunotherapy treatments is very difficult to treat, and patients urgently need new options. This medication is being tested because it may help the immune system recognize and fight cancer cells more effectively than currently available treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive as an intravenous infusion (through an IV in your arm) on a regular schedule determined by the study team. You would have multiple clinic visits for treatment administration, blood tests, and imaging scans to monitor how your cancer is responding. The study is designed to follow you over time to track how long the treatment helps control your cancer and to monitor for any side effects. Participation typically involves ongoing visits and assessments, though the exact schedule will be explained to you by the research team.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
M.D. Anderson Cancer Center
Collaborators
Akesobio Australia Pty Ltd, Summit Therapeutics
Enrollment target
~90 participants
Started
July 2025
Primary completion
July 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Saurav Haldar, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.